http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Cariogenic Activity in Saliva of Korean Head and Neck Cancer Patients
Hae-Soon Lim,Kyung-Yi Chung,Ae-Ok Kim,Mi-Ran Kim,Youn-Shin Kim,Mi-Sun Kang,Jeong-Won Hong,Ji-Yeon Jung,Ji-Il Park,Guem-Sug Lee KOREAN ACADAMY OF ORAL BIOLOGY 2014 International Journal of Oral Biology Vol.39 No.2
The purpose of this study is to evaluate salivary flow rate,salivary pH, and cariogenic activity using unstimulatedsaliva of the head and neck cancer patients. Twenty threecancer patients (19 males, 4 females) who had undergonechemotherapy and radiation therapy and twenty four healthyvolunteers (14 males, 10 females) as a control were included. Salivary flow rate, salivary pH, and cariogenic activity usingunstimulated saliva were examined. Compared to saliva ofthe control group, salivary flow rate (p<0.001) and salivarypH (p<0.001) were significantly lower in head and neckcancer patients. The colony counts of Lactobacilli was higherin head and neck cancer patients (p<0.05) than in controlgroup. These salivary factors and cariogenic activity canincrease the prevalence of dental caries in head and neckcancer patients.
Hae Won Lee,Woo Youl Kang,Ji Seo Park,Jae Hwa Lee,Mi-Ri Gwon,Dong Heon Yang,Eun Hee Kim,Soo-Jin Park,Young-Ran Yoon,Sook Jin Seong 대한임상약리학회 2023 Translational and Clinical Pharmacology Vol.31 No.2
Two open-label, randomized, two-period crossover studies were conducted to investigate the pharmacokinetic (PK) properties, safety, and bioequivalence of the test formulation (KD4004), a new fixed-dose combination (FDC) formulation of dapagliflozin and metformin extended release (XR) tablets, relative to the reference formulation (10 mg dapagliflozin/1,000 mg metformin XR FDC tablet) in healthy subjects under fasting (Part A) and fed (Part B) conditions. After giving the dose, serial blood samples were collected for a period of 48 hours. Primary PK parameters (AUC 0-t and C max ) were used to assess bioequivalence between two dapagliflozin/metformin XR (10/1,000 mg) FDC formulations under fed and fasting conditions. Safety and tolerability were also evaluated. Part A and Part B were completed by 32 and 37 subjects, respectively. Bioequivalence of the two FDC formulations of dapagliflozin and metformin XR tablets was established in both the fasted and the fed conditions as the 90% confidence interval of the ratios of adjusted geometric means for AUC 0-t and C max were contained within the predefined range of 0.800–1.250 bioequivalence criteria. Single-dose administration of dapagliflozin and metformin XR was safe and well tolerated as the two FDC formulations. In conclusion, both FDC formulations of dapagliflozin and metformin XR tablets were bioequivalent in fed and fasted subjects. All treatments were well tolerated.
Hae Won Lee,Woo Youl Kang,Mi-Ri Gwon,Eun Jung Choi,Eun Hee Kim,Kyunghee Cho,Bakhwan Lee,Sook Jin Seong,Young-Ran Yoon 대한임상약리학회 2022 Translational and Clinical Pharmacology Vol.30 No.3
A new fixed-dose combination (FDC) formulation of raloxifene 60 mg and cholecalciferol 800IU was developed to improve the medication compliance and overall efficacy of raloxifenetreatment in postmenopausal osteoporosis patients. The aim of this study was to comparethe pharmacokinetics between two tablets of FDC formulation of raloxifene/cholecalciferoland the two products administered concomitantly at respective doses. This randomized,open-label, single-dose, two-treatment, two-way crossover study included 46 volunteers. During each treatment period, subjects received the test formulation (FDC formulationcontaining raloxifene and cholecalciferol) or the reference formulation (co-administration ofraloxifene and cholecalciferol), with a 14-d washout period. Serial blood samples were collectedperiodically over 96 hours after drug intake. In total, 46 subjects completed the study. Thegeometric mean ratios and its 90% confidence inter vals of the FDC to the single agents for thearea under the concentration-time cur ve from zero to the last quantifiable time point and themaximum plasma concentration met the regulator y criteria for bioequivalence: 1.1364 (1.0584–1.2201) and 1.1010 (0.9945–1.2188) for raloxifene and 1.0266 (0.9591–1.0989) and 1.0354(0.9816–1.0921) for baseline-corrected cholecalciferol, respectively. Both formulations were welltolerated. No significant differences was obser ved in the incidence of adverse events betweenthe two treatments. It was concluded that two tablets of the newly developed FDC formulationof raloxifene and cholecalciferol and the corresponding two agents administered concomitantlyat respective doses were bioequivalent.
( Hae Won Lee ),( Sook Jin Seong ),( Sung Min Park ),( Joo Mi Lee ),( Mi Ri Gwon ),( Hyun Ju Kim ),( Sung Mook Lim ),( Mi Sun Lim ),( Woo Mi Kim ),( Dong Heon Yang ),( Young Ran Yoon ) 영남대학교 약품개발연구소 2015 영남대학교 약품개발연구소 연구업적집 Vol.25 No.-
Background: Imatinb mesyI-ate(IM)is a selective tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and gastrointestihnal stromal tumors.A new once-daily 400-mg film-coated tablet of imatinib has been developed by a pharmaceutical company in Korea. Objective: The present study was designed to assess and compare the PK parameters, bioavailability,and bioequivalence of the new imatinib 400-mg formulation(test)versus the conventional 100-mg formulation (reference)administered as a single 400-mg dose in healthy adult male volunteers. Methods: This randomized, open-label,single-dose, two-way crossover study was conducted in healthy Korean male volunteers. Eligible subjects were randomly assigned in a 1:1 ratio to recetive 400 mg of the test (one 400-mg tablet)or reference (four 100-mg tables)formulation, followed by a 2-week washout period and administrationof the alternate formulation. Serial bloodssamples were collected at 0(predose),0.5,1,1.5,2,2.5,3,4,6,8,10,12,24,48,and 72 hours after administration.Plasma imatinib concentrations were determined using liquid chromatography coupled with tandem mass spectrometry. The formulations were to be considered bipequivalent if the 90% confidence intervals (CIs)of the adjusted geometric mean ratios for C(max,)AUCo-t, and AUCo-(oo)were within the predetermined range of 0.80-1.25.REsult; In total, 35 subjects completed the study. No serious advers event was reported during study.The 90%Cls of the adjusted geometric mean ratios of the test formulation to the refence formulation for Cmax, AUCo-oo of imatimib were all within the bioequivalence criteria range of 0.8-10.1.25.Conclusions: The test formulation of imatinib met the Lorean regulatory requirements for bioequivalence, Both imatinib formulations were well-toler-ated in all subjects.
Lee, Sang-Min,Wang, Joong-San,Park, Sung-Kyu,Kim, Hong-Rae,Ko, Jin-Hee,Oh, Yu-Jung,Yoon, Hae-Ran,Kim, Ji-Sung International Academy of Physical Therapy Research 2012 Journal of International Academy of Physical Ther Vol.3 No.1
The aim of this study was to investigate the correlation among bone mineral density(BMD), body composition and body circumference on 20's college women in Hwaseong. A total of 86 subjects were measured with BMD and body composition and body circumference. To evaluate the correlation between BMD and body composition, bone density and body weight, body mass index(BMI), lean body mass, muscle mass, fat mass and body fat mass were compared. The results of this study, weight was considered the strong correlation with BMD than the height and BMI seems to be greater significance rather than the lumbar spine and femur BMD. In addition, the relationship between body composition and BMD, lean body mass, muscle mass, body fat mass were the most relevant factors and BMD. The relationship between BMD and body circumference that have been difficult because of not enough previous studies but somewhat the study showed that association.
Hae June Lee,Joong Sun Kim,Changjong Moon,Jong Choon Kim,Chun Sik Bae,Sung Soo Kang,Uhee Jung,Hae Ran Park,Sung Kee Jo,Sung Ho Kim 한국실험동물학회 2009 Laboratory Animal Research Vol.25 No.1
The morphological changes of small intestine and protective properties of an herbal preparation (HemoHIM) in intestinal damages were examined by evaluating its effects on jejunal crypt survival, apoptosis and other histological assessment in 5-fluorouracil (5-FU)-treated mice. The female ICR mice were treated with 5-FU for the examination of jejunal crypt survival and any morphological changes (200 ㎎/㎏ of body weight, i.p.), and for the detection of apoptosis (40 ㎎/㎏ of body weight, i.p.). HemoHIM was administered intraperitoneally at a dosage of 50 ㎎/㎏ of body weight at 36 and 12 hours preirradiation and 30 minutes post-irradiation, or orally at a dosage of 250 ㎎/㎏ of body weight/day for 7 or 11 days before autopsy. Compared to normal controls, 5-FU increased the incidence of apoptosis by 20-fold. 5-FU decreased villus height in the jejunum (44.6%) with crypt depths increased by 18.6% in this gut region. In comparison with normal controls, the values of basal lamina length of 10 enterocytes in the jejunum were significantly higher in 5-FU treated mice (55.5%). These effects were less profound in HemoHIM treated mice in which apoptosis was decreased 11.4% (p.o.) and 27.4% (i.p.), with villus height increased by 37% (p.o.) and 28% (i.p.), crypt depth by 13.4% (p.o.) and 19.0% (i.p.) and accompanied by decreases in basal lamina length of 23.5% (p.o.) and 31.9% (i.p.), compared to 5-FU control group. These results suggested that HemoHIM may be therapeutically useful to reduce intestinal injury following 5-FU treatment.